br Funding br Acknowledgments br The authors thank Dr

Funding
Acknowledgments
The authors thank Dr. Yu-Xin Li (National Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University) and Dr. Li-Ning Miao (Department of Nephrology, the Second Hospital of Jilin University) for helpful technical instruction.
References
[1] D.S.P. Tan, R. Agarwal, S.B. Kaye, Mechanisms of transcoelomic metastasis in ovarian cancer, Lancet Oncol. 7 (11) (2006) 925–934. [2] Ovarian Cancer Association Consortium Members of the EWG SC, in alphabetical order, Epidemiology Working Group Steering Committee, J.A. Doherty, A. Jensen, L.E. Kelemen, C.L. Pearce, E. Poole, J.M. Schildkraut, K.L. Terry, S.S. Tworoger, P.M. Webb, N. Wentzensen, Current gaps in ovarian Cancer epidemiology: the need for new population-based research, J. Natl. Cancer Inst. 109 (10) (2017).
C. Muller-Tidow, P. Dreger, M. Schmitt, Differences in expansion potential of naive chimeric antigen receptor t FITC-Dextran from healthy donors and untreated chronic lym-phocytic leukemia patients, Front. Immunol. 8 (2017) 1956.
[36] M. Ploug, Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist, Theranostics 3 (7) (2013) 467–476.
A. Ugolkov, O. Dubrovskyi, T.V. O’Halloran, M. Huang, A.P. Mazar, Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (alphaM), PLoS One 9 (1) (2014) e85349.
G. Dranoff, J. Ritz, S. Nikiforow, Phase I trial of autologous CAR t cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma, Cancer Immunol. Res. (2018).
Contents lists available at ScienceDirect
Future Generation Computer Systems
journal homepage: www.elsevier.com/locate/fgcs
Bayesian analysis model for the use of anesthetic analgesic drugs in cancer patients based on geometry reconstruction
Zhichao Wu a,∗, Han Wang a, N. Arunkumar b a Department of Anesthesiology, Nanchong Central Hospital, Nanchong, Sichuan 637000, PR China b SASTRA University, Thanjavur, India
• Anesthetic analgesic drugs in patients with cancer pain is analysed.
• Bayesian Algorithm of geometric reconstruction is used for Genetic code analysis.
• The parameters such as dosage, pain and specifications of the drugs are considered.
Article history:
Keywords:
Tumor
Pain
Anesthesia
Analgesia 
The use of anesthetic analgesic drugs in patients with cancer pain is analyzed comprehensively, which provides the necessary reference for rational use of drugs in clinic. Method: 102 patients with cancer pain are selected from a municipal people’s hospital from 2014 to 2016 in China. Based on the Bayesian algorithm of geometric reconstruction, the variety, dosage, prescription number, specification and frequency of anesthetic analgesic drugs used by patients are analyzed comprehensively. Results: the anesthetic analgesic drugs used by 102 patients with cancer pain mainly include Morphine Hydrochloride Injection, Tramadol Injection, Dezocine Injection, Morphine Hydrochloride Sustained-release Tablets, Tramadol Hydrochloride Sustained-release Tablets, Oxycodone Hydrochloride Sustained-release Tablets and Fentanyl Transparent Dressing. Among them, the dosage of Morphine Hydrochloride Sustained-release Tablets is the highest, followed by Tramadol Hydrochloride Sustained-release Tablets, Oxycodone Hydrochloride Sustained-release Tablets, Fentanyl Transparent Dressing, Morphine Hydrochloride Injec-tion, Tramadol Injection and Dezocine Injection. The drug use frequency of Fentanyl Transparent Dressing is the highest and the lowest is Dezocine Injection. The drug utilization index of Oxycodone Hydrochloride Sustained-release Tablets is the lowest, and that of Morphine Hydrochloride Sustained-release Tablets is the highest. Conclusion: The use principle of anesthetic analgesic drugs for cancer patient with pain basically conforms to the three-step analgesic principle of cancer pain, and the dosages and specifications of anesthetic drugs are basically reasonable, but need to be further standardized and rationalized.